Company Profile

**Industry Sector:** Orthobiologics/Medical Devices

**Company Overview:** Carmell Therapeutics is a clinical stage company developing products made from blood plasma. Plasma-based materials (PBMs) provide clinicians with novel, application-specific, and cost-effective strategies to accelerate the repair of damaged tissue and reduce complications. Carmell’s first product is a putty for treating open fractures, which has been shown clinically to promote healing of both the fracture and surrounding soft tissues while reducing infections.

**Target Market(s):** Orthopaedic Trauma Surgeons and Trauma Centers

Key Value Drivers

**Technology:** The REPAIR™ Putty has the potential to reduce healthcare costs, with less hospitalization time and reduced infections. PBMs not only bathe injured tissues with regenerative factors but also appear to recruit the body’s innate immune system to reduce infections, avoiding the problems associated with antibiotic-resistant infections.

**Competitive Advantage:** PBMs have uniquely low manufacturing costs and can be stored at room temperatures. The Company has 16 issued patents broadly covering the technology and products.

**Plan & Strategy:** Use clinical data for EU market approval and pre-submission meeting with FDA for pivotal clinical study and market approval strategy.

Management

**Leadership:** Alan West, CEO  
Jason Smith, PhD, Director R&D

**Scientific Advisory Board:**  
Phil Campbell, PhD, founder, CSO (Carnegie Mellon U.)  
Stephen Badylak, DVM, PhD, MD (U. Pittsburgh)  
Darrell Triulzi, MD (UPMC, Inst. Transfusion Med.)  
Col. Bill Rodkey, DVM (retired) (Steadman Philippon, Vail, CO)  
Savio Woo, PhD (U. Pittsburgh)

Product Pipeline

1. **Pipeline One:** Next generation putty products for antimicrobial, implant coating, and bone filler applications

2. **Pipeline Two:** Injectable products for ligament, tendon, and muscle injuries (sports medicine)

3. **Pipeline Three:** Soft tissue products for burn and ulcer applications (advanced wound care)